← Back to Screener
Atara Biotherapeutics, Inc (ATRA)
Price$9.92
Value ScoreB
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-42.23%
Price vs S&P 500 (4W)18.95%
VGM Score42.79
Market Capitalization$89.38M
P/E Ratio (Annual)2.73x
All Metrics
Book Value / Share (Quarterly)$0.07
P/TBV (Annual)0.52x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)23.85%
Cash Flow / Share (Quarterly)$-3.04
Price vs S&P 500 (YTD)-53.32%
Gross Margin (TTM)96.12%
Net Profit Margin (TTM)-40.91%
EPS (TTM)$-0.86
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-0.86
EPS (Annual)$2.57
ROI (Annual)-174.14%
Gross Margin (Annual)82.44%
Net Profit Margin (5Y Avg)-1058.29%
Cash / Share (Quarterly)$0.98
P/E Basic Excl Extra (TTM)2.50x
Revenue Growth QoQ (YoY)-99.47%
P/E Normalized (Annual)2.73x
ROA (Last FY)161.54%
Revenue Growth TTM (YoY)-88.41%
EBITD / Share (TTM)$-0.50
ROE (5Y Avg)-107.29%
Operating Margin (TTM)-27.27%
Cash Flow / Share (Annual)$-6.96
P/B Ratio12.08x
P/B Ratio (Quarterly)21.32x
Net Income / Employee (Annual)$2,334,900
EV / Revenue (TTM)5.29x
Net Interest Coverage (TTM)11.52x
ROA (TTM)-35.29%
EV / EBITDA (TTM)3.23x
EPS Incl Extra (Annual)$2.57
Current Ratio (Annual)0.82x
Quick Ratio (Quarterly)2.16x
3-Month Avg Trading Volume1.11M
52-Week Price Return17.81%
P/E Incl Extra (TTM)2.50x
Revenue / Employee (TTM)$1,652,800
Tangible BV / Share (Quarterly)$-0.50
P/S Ratio (Annual)0.74x
Asset Turnover (Annual)5.97x
52-Week High$19.14
Operating Margin (5Y Avg)-1073.92%
EPS Excl Extra (Annual)$2.57
CapEx CAGR (5Y)-46.72%
Tangible BV CAGR (5Y)-6.57%
26-Week Price Return-34.30%
Quick Ratio (Annual)0.82x
13-Week Price Return98.40%
Total Debt / Equity (Annual)0.04x
Current Ratio (Quarterly)2.16x
Enterprise Value$122.49M
Asset Turnover (TTM)0.86x
Book Value / Share Growth (5Y)-25.61%
Revenue / Employee (Annual)$8,626,600
Inventory Turnover (Annual)3.98x
Pretax Margin (Annual)27.09%
Cash / Share (Annual)$1.16
3-Month Return Std Dev210.85%
Net Income / Employee (TTM)$-676,200
ROE (Last FY)-180.33%
Net Interest Coverage (Annual)-2.04x
EPS Basic Excl Extra (Annual)$2.57
Receivables Turnover (TTM)5.21x
Total Debt / Equity (Quarterly)0.12x
EPS Incl Extra (TTM)$-0.86
Receivables Turnover (Annual)88.32x
ROI (TTM)-306.84%
P/S Ratio (TTM)3.86x
Pretax Margin (5Y Avg)-1058.21%
Revenue / Share (Annual)$9.50
Tangible BV / Share (Annual)$1.32
Forward P/E169.94x
Price vs S&P 500 (52W)-6.55%
P/E Ratio (TTM)2.50x
Year-to-Date Return-45.16%
5-Day Price Return-3.50%
EPS Normalized (Annual)$2.57
ROA (5Y Avg)-43.38%
Net Profit Margin (Annual)27.07%
Month-to-Date Return-5.61%
Cash Flow / Share (TTM)$-2.73
EBITD / Share (Annual)$2.99
Operating Margin (Annual)29.69%
LT Debt / Equity (Annual)26.75x
ROI (5Y Avg)-105.99%
P/E Excl Extra (TTM)2.50x
EPS Basic Excl Extra (TTM)$-0.86
P/B Ratio (Annual)2.46x
Inventory Turnover (TTM)3.98x
Pretax Margin (TTM)-40.78%
Book Value / Share (Annual)$1.32
Price vs S&P 500 (13W)90.15%
Beta0.14x
Revenue / Share (TTM)$2.72
ROE (TTM)-315.42%
52-Week Low$3.92
vGradeB
gGradeF
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.29est. -0.41
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
3.73
3.80
3.80
4.00
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ATRAAtara Biotherapeutics, Inc | B | F | B | $9.92 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Atara Biotherapeutics develops cell therapies targeting serious diseases including solid tumors, hematologic cancers, and autoimmune disorders. The company's CAR T platform includes product candidates Tab-cel, ATA188, and ATA3219 in its development pipeline.